Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Johns Hopkins University
Age
18–100
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Clinically diagnosed or histologically proven stage II-IV renal cell carcinoma
Completed staging evaluation with computed tomography (CT) or magnetic resonance imaging (MRI) of the chest, abdomen and pelvis ≤90 days prior to study enrollment
You may not be if
History of other malignancy diagnosed within the last 3 years (with the exception of low risk prostate cancer, ductal carcinoma in situ of the breast, squamous cell carcinoma or basal cell carcinoma of the skin)
Administered a radioisotope within 5 physical half-lives prior to study enrollment
Pregnancy ((as determined in accordance with the policies of the positron emission tomography (PET) center))
Intention to enroll in a blinded therapeutic clinical trial following Positron emission tomography-computed tomography (PET/CT)
Clareo Health | Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma
